We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Test Uses AI to Detect Peripheral Artery Disease

By LabMedica International staff writers
Posted on 20 Nov 2017
Researchers from the Massachusetts General Hospital and Prevencio, Inc. More...
(Kirkland, Washington; USA) have developed a simple new blood test which accurately diagnoses significant Peripheral Artery Disease (PAD), a circulatory problem in which plaque-narrowed arteries reduce blood flow to a patient’s limbs and kidneys. According to the data presented at American Heart Association 2017 Scientific Sessions, the test could be used as a gatekeeper to imaging or invasive testing, thereby reducing cost and exposures to intravenous contrast and/or ionizing radiation.

Prevencio employs machine learning, a state-of-the-art sub-set of artificial intelligence, and big data analytics to interrogate well-characterized clinical data sets. It focuses on diagnostic and predictive tests for cardiovascular disease and related adverse events, as well as for cardiovascular pharmaceutical research. The company’s proprietary HART Tests are leading the way in the proteomics and artificial intelligence era of improving cardiovascular medical care.

In the study, the researchers developed and validated a multi-protein blood test, HART PAD, which identifies the presence of PAD and predicts the need for a future medical intervention. The researchers tested 355 patients referred for diagnostic peripheral angiography and/or coronary angiography to Massachusetts General Hospital. When divided into low-risk and high-risk categories, the test predicted with 98% accuracy to exclude obstruction of the peripheral arteries. Additionally, the test predicted with 86% accuracy to identify obstruction of the peripheral arteries.

“This blood test may allow for the diagnosis and treatment of many more patients with PAD,” said James L. Januzzi, MD, Principal Investigator and a practicing cardiologist at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. “And in addition to the opportunity for more appropriate care of patients, we believe it could benefit more cardiac clinical trials, by saving time and thereby lowering overall trial costs.”

“We are pleased to work with Massachusetts General Hospital, Dr. Januzzi and his researchers, and Myriad RBM to develop novel and highly accurate blood tests to improve diagnosis and treatment for millions of cardiovascular patients,” said Rhonda Rhyne, Prevencio’s Chief Executive Officer. “It is also highly rewarding to work with pharmaceutical companies to improve drug development and decrease clinical trial expenses.”

Related Links:
Prevencio


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Portable Electronic Pipette
Mini 96
New
Sample Transportation System
Tempus1800 Necto
New
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The study highlights the potential of cCAFs as a biomarker for early diagnosis and prognosis (H J Woo et al., Analytical Chemistry (2025). DOI: 10.1021/acs.analchem.5c02154)

Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy

Accurate cancer diagnosis remains a challenge, as liquid biopsy techniques often fail to capture the complexity of tumor biology. Traditional systems for isolating circulating tumor cells (CTCs) vary in... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.